Gaia, Inc. and Daiichi Sankyo Europe announced an exclusive partnership to develop and launch a digital therapeutic named "lipodia" for adults with hypercholesterolemia, targeting the German market initially with plans for broader European rollout.
Under the agreement, Gaia will supply its proprietary digital platform and content library, while Daiichi Sankyo will provide clinical data, regulatory support, and distribution. The collaboration aims to combine Gaia's digital engagement expertise with Daiichi Sankyo's clinical development and regulatory capabilities to bring an evidence‑based therapeutic to patients across Europe.
The partnership represents a significant diversification for Gaia, which has been expanding beyond its core subscription video‑on‑demand business. Gaia's Q4 2025 revenue reached $25.5 million, a 20% year‑over‑year increase, while the company reported a net loss of $0.5 million, underscoring its focus on growth and margin improvement.
For Daiichi Sankyo, the deal expands its cardiovascular portfolio, which already includes non‑statin agents Nilemdo and Nustendi. The digital therapeutic aligns with the company's Digital Innovation Hub, positioning it to offer integrated pharmaceutical and digital solutions for heart health.
Management highlighted the strategic fit: Oliver Appelhans said, "Digital therapeutics represent an important next step in delivering holistic heart health. By combining pharmaceuticals with evidence‑based digital therapeutics, we can support patients beyond our medicines." Gaia's chairman Jirka Rysavy noted the company's momentum, and CEO Kiersten Medvedich emphasized the company’s focus on AI‑driven engagement and sustainable growth.
The collaboration is expected to create a new revenue stream for Gaia and broaden its footprint in the growing digital health sector, while providing Daiichi Sankyo with a platform to extend its cardiovascular offerings beyond traditional drugs.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.